Zai Lab and Novocure Share Positive Results from Phase III Clinical Trial for Pancreatic Cancer
The PANOVA-3 study met its primary endpoint, demonstrating an improvement in overall survival for patients treated with Tumor Treating Fields.
Zai Lab and Novocure have announced positive results from the Phase III PANOVA-3 clinical trial. The study, evaluating the use of Tumor Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for pancreatic cancer, met its primary endpoint by demonstrating a statistically significant improvement in median overall survival (mOS).1
PANOVA-3 is a prospective, randomized open-label, controlled trial. In addition to the primary endpoint of OS, secondary endpoints include progression free survival, local progression free survival, and objective response rate. The study enrolled 571 patients, randomized 1:1, and were followed for a minimum of 18 months.
“As a researcher and clinician, I have experienced the challenges of developing treatments in pancreatic cancer. It is exciting to see the PANOVA-3 trial achieve the positive primary endpoint of overall survival, a landmark outcome for this field,” Vincent Picozzi, MD, medical oncologist and investigator in the PANOVA-3 trial, said in a press release. “These data for Tumor Treating Fields are very promising, especially in this difficult to treat patient population.”
According to study results, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, showing a statistically significant improvement.
“PANOVA-3 is the first and only Phase III trial to demonstrate a statistically significant benefit in overall survival specifically in unresectable, locally advanced pancreatic cancer, and is Novocure’s third positive Phase III clinical trial in the last two years,” Nicolas Leupin, MD, PhD, chief medical officer, Novocure, said in the press release. “We are grateful to the patients and investigators for their participation in the trial, and we look forward to sharing the full data at an upcoming medical conference.”
Additional results from the trial show survival rate benefit for patients treated with TTFields increased with a 13% improvement in OS at 12 months and a 33% improvement in survival rate at 24 months.
Rafael Amado, MD, president, head of global research and development at Zai Lab added, “There are approximately 134,000 new cases of pancreatic cancer diagnosed annually in China, and this cancer is one of the most challenging to treat globally, with limited effective treatment options and poor survival outcomes. Demonstrating a statistically significant and clinically meaningful improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer is an important achievement. We are pleased to have been able to contribute to the PANOVA-3 study, and we look forward to working with Novocure to bring this therapy to patients as soon as possible.”
Based on results from the PANOVA-3 trial, Novocure will file for regulatory approval in the US, EU, Japan, and other key markets, while Zai Lab intends to file for approval in China.
Reference
1. Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer. News release. Zai Lab. December 2, 2024. Accessed December 2, 2024. https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Data Show Efficacy of Tezspire Treating Chronic Rhinosinusitis with Nasal Polyps
March 4th 2025Phase III WAYPOINT trial shows Tezspire (tezepelumab) significantly reduces nasal polyp size and congestion severity in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, while also decreasing the need for surgery and systemic glucocorticoids.
